4.7 Article

Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system

期刊

DRUG DELIVERY
卷 14, 期 1, 页码 25-31

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/10717540600559510

关键词

amino acids; BBB targeting; brain targeted drug delivery; BTDS; cerebrovasculature; disulfides; LAT1; LAT2; neuropharmaceuticals

资金

  1. NCI NIH HHS [CA74377] Funding Source: Medline
  2. NATIONAL CANCER INSTITUTE [R15CA074377] Funding Source: NIH RePORTER

向作者/读者索取更多资源

We describe a novel strategy to achieve high affinity recognition for the specific, cerebrovascular large neutral amino acid transporter (LAT1) isoform by covalent coupling of small molecules to the amino acid, L-cysteine (L-Cys). L-Cys ( as the carrier) was covalently attached via a disulfide bond to either 6-mercaptopurine or 2-methyl-1-propanethiol (IBM) to form the brain-targeted drug delivery systems (BTDS). BTDS were designed for high affinity recognition by LAT1 at the cerebrovasculature. Using an in situ rat brain perfusion technique, competition between BTDS and the radiotracer [C-14] L-Leu demonstrated significant inhibition of [C-14] L-Leu brain uptake. BTDS possess affinity for cerebrovascular LAT1 in many distinct brain compartments, and the recognition of BTDS by LAT1 is influenced by hydrophobicity of the side-chain in BTDS. Thus, the BTDS strategy may be utilized for rapid shuttling of various neuropharmaceuticals into brain.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据